^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
BIOMARKER:

FLT3-ITD mutation + MLL rearrangement

i
Other names: FLT3, Fms Related Tyrosine Kinase 3, Receptor-Type Tyrosine-Protein Kinase FLT3, Stem Cell Tyrosine Kinase 1, Fms-Like Tyrosine Kinase 3, CD135, FLK-2, STK1, Growth Factor Receptor Tyrosine Kinase Type III, Fetal Liver Kinase 2, HTRX1, HTRX, MLL1A, Mixed Lineage Leukemia 1, Myeloid/Lymphoid Or Mixed-Lineage Leukemia Protein 1, CXXC7, MLL1, TRX1, Zinc Finger Protein HRX, Trithorax-Like Protein, ALL-1, Lysine (K)-Specific Methyltransferase 2A, CXXC-Type Zinc Finger Protein 7, Histone-Lysine N-Meth
Entrez ID:
over2years
Clinical Significance of Common Gene Mutations in 53 Patients with Acute Myeloid Leukemia Harboring 11q23/MLL Rearrangements (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi)
A relatively high mutation frequency is observed in AML patients with 11q23/MLL rearrangements and most cases shows single mutation. The RAS signaling pathway alterations are most common. Gene mutation does not affect the OS of these patients, who show poor prognosis. A significantly higher Hb at initial diagnosis in FLT3 mutated patients is significantly higher than that in FLT3 wild-type cases. Patients who underwent HSCT show a better prognosis than those only received chemotherapy.
Clinical • Journal
|
FLT3 (Fms-related tyrosine kinase 3) • KIT (KIT proto-oncogene, receptor tyrosine kinase) • NPM1 (Nucleophosmin 1) • DNMT3A (DNA methyltransferase 1) • ASXL1 (ASXL Transcriptional Regulator 1) • EZH2 (Enhancer of zeste 2 polycomb repressive complex 2 subunit) • TET2 (Tet Methylcytosine Dioxygenase 2) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
|
NRAS mutation • FLT3-ITD mutation • FLT3 mutation • NPM1 mutation • KIT mutation • DNMT3A mutation • ASXL1 mutation • TET2 mutation • EZH2 mutation • FLT3-TKD mutation • MLL rearrangement • CEBPA mutation • DNMT3A mutation + FLT3-ITD mutation • WT1 mutation • FLT3-ITD mutation + MLL rearrangement • FLT3 mutation + DNMT3A mutation • NPM1 mutation + DNMT3A mutation • NPM1 mutation + NRAS mutation